Page 142 - Demo

17.2. Quantitative disclosures
1 Number of meetings held by the Remuneration Committee during the financial year and remuneration paid to its members.
2 Number of employees having received a variable remuneration award during the year.
335 Number and total amount of sign-on awards made during the financial year.
4 Details of guaranteed bonus, if any, paid as joining / sign on bonus.
5 Details of severance pay, in addition to accrued benefits, if any.
636 Total amount of outstanding deferred remuneration, split into cash, shares and share-linked instruments and other forms.
7 Total amount of deferred remuneration paid out in the financial year.
8 Breakdown of amount of remuneration awards for the financial year to show fixed and variable, deferred and non-deferred.
9 Total amount of outstanding deferred remuneration and retained remuneration exposed to ex post explicit and / or implicit adjustments.
10 total amount of reductions during the financial year due to ex- post explicit adjustments.
11 total amount of reductions during the financial year due to ex- post implicit adjustments.
Total Meeting Held: 9
Total sitting fee paid: `16.20 Lakhs
8 employees
(Current MD&CEO/ Ex-MD&CEO/ CFO /CRO /CBO / Current Head of Treasury / Ex-Head of Treasury / CS ) `37.99 Lakhs
NIL
NIL
> ** Cash : `52.68 Lakhs
> *** ESPS shares : `28.85 Lakhs
> **** ESOP grants : `4.38 Lakhs
(Current MD&CEO/ Ex-MD&CEO/ CFO /CRO /CBO / Current Head of Treasury / Ex-Head of Treasury / CS )
`18.17 Lakhs (Current MD&CEO/ Ex-MD&CEO/ CFO / CRO /CBO / Current Head of Treasury / Ex-Head of Treasury / CS )
> Fixed gross : `815.20 Lakhs
> Variable deferred : `18.17 Lakhs
(Current MD&CEO/ Ex-MD&CEO/ CFO /CRO /CBO / Current Head of Treasury / Ex-Head of Treasury / CS )
sl. no
Quantitative disclosures (covers only Whole time directors/ ceo/other risk takers34)
numbers
NIL
NIL NIL
18. Table DF-17: SuMMary coMPariSon oF accounTinG aSSeTS vS. leveraGe raTio eXPosure Measure
1 total consolidated assets as per published financial statements
2 Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for
accounting purposes but outside the scope of regulatory consolidation
3 Adjustment for fiduciary assets recognised on the balance sheet pursuant to the operative accounting
framework but excluded from the leverage ratio exposure measure
4 Adjustments for derivative financial instruments
5 Adjustment for securities financing transactions (i.e. repos and similar secured lending)
6 Adjustment for off-balance sheet items (i.e. conversion to credit equivalent amounts of off- balance sheet
exposures)
7 Other Adjustments
8 leverage ratio exposure
34 Key material risk takers are internally defined as mentioned in row 2 of the above table.
35 ESOPs basis RBI approval as sign-on grants to Current MD&CEO; vesting due over 2 years – 2020 and 2021
` in Lakhs
1,452,076 306,347
-
- 82,700 1,155
-15,420
1,826,857
Summary comparison of accounting assets versus leverage ratio exposure measure
item
amount
36 ** For current-MD&CEO and Ex-MD&CEO, Target Variable Pay provisioned and notional amount has been provisioned. The actual amount will be decided post closure of Annual Performance reviews. It will be planned based on NRC guidance and paid basis RBI approval.
> For all 8 employees, amount is provisioned for variable pay for 50% of total target variable pay due for payment in FY 20-21. Actual payment will be subject to Bank and Individual performance.
*** Including 26,90,000 shares allotted to Ex-MD&CEO
**** Excluding ESOPs of current MD&CEO since it was granted as sign-on grant. ESOPs are granted but not exercised.
140 | AnnuAl RepoRt 2019-20